Literature DB >> 7977318

Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure.

S C Greaves1, G D Gamble, J F Collins, G A Whalley, D N Sharpe.   

Abstract

To evaluate determinants of left ventricular hypertrophy (LVH) and left ventricular (LV) systolic dysfunction in chronic renal failure (CRF), M-mode and two-dimensional echocardiography were performed in 38 undialyzed patients with CRF (serum creatinine > or = 3.4 mg/dL), 54 patients receiving continuous ambulatory peritoneal dialysis, 30 patients receiving hemodialysis, and 59 healthy age- and sex-matched volunteers. Left ventricular (LV) wall thickness and LV dimensions were greatest in dialysis patients, intermediate in CRF patients, and least in control subjects. LV mass index calculated from M-mode measurements was 78.7 g/m2 +/- 14.8 g/m2 in controls, 120.5 g/m2 +/- 28.7 g/m2 in CRF patients, and 136 +/- 45.0 g/m2 in dialysis patients (P < 0.0001). LV fractional shortening and LV velocity of circumferential shortening were lower in dialysis patients than in CRF patients and controls (fractional shortening 36.5% +/- 5.6% in controls, 36.2% +/- 7.2% in CRF patients, and 29.8% +/- 8.9% in dialysis patients; P < 0.0001). Echocardiography was normal in only 24 dialysis patients (29%) and 14 CRF patients (37%) (P = NS). Thirty-nine dialysis patients (46%) and 10 CRF patients (26%) had LVH (P = NS). Thirty dialysis patients (36%) and five CRF patients (13%) had LV systolic dysfunction (P < 0.05). LV hypertrophy with LV systolic dysfunction was present in 15 dialysis patients but no CRF patients (P < 0.05). There were no significant differences between hemodialysis patients and continuous ambulatory peritoneal dialysis patients in M-mode echocardiographic measurements or the frequency of LVH and LV systolic dysfunction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7977318     DOI: 10.1016/s0272-6386(12)80670-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease.

Authors:  Jason Payne; Smriti Sharma; Dexter De Leon; Jun L Lu; Fregenet Alemu; Rasheed A Balogun; Sandra M Malakauskas; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

2.  Antihypertensive treatment in patients with end-stage renal disease.

Authors:  Mensura Ascerić; Nedzad Mulabegović; Sabina Nuhbegović; Alma Nadarević; Muamera Mujcinagić-Vrabac
Journal:  Bosn J Basic Med Sci       Date:  2005-11       Impact factor: 3.363

3.  When does the cardiovascular disease appear in patients with chronic kidney disease?

Authors:  Betul Sozeri; Sevgi Mir; Orhan Deniz Kara; Erturk Levent
Journal:  Pediatr Cardiol       Date:  2010-04-17       Impact factor: 1.655

4.  Office and ambulatory blood pressure elevation in children with chronic renal failure.

Authors:  Mark M Mitsnefes; Thomas R Kimball; Stephen R Daniels
Journal:  Pediatr Nephrol       Date:  2002-12-18       Impact factor: 3.714

5.  Left ventricular dysfunction in the haemodialysis population.

Authors:  Manish M Sood; Robert P Pauly; Claudio Rigatto; Paul Komenda
Journal:  NDT Plus       Date:  2008-08

6.  Carotid intima-media thickness and left ventricular hypertrophy in hemodialysis patients.

Authors:  Mahmoud Rafieian-Kopaei; Hamid Nasri
Journal:  J Renal Inj Prev       Date:  2013-10-10

7.  Diastolic dysfunction is an independent predictor of cardiovascular events in incident dialysis patients with preserved systolic function.

Authors:  Jae Hyun Han; Ji Suk Han; Eun Jin Kim; Fa Mee Doh; Hyang Mo Koo; Chan Ho Kim; Mi Jung Lee; Hyung Jung Oh; Jung Tak Park; Seung Hyeok Han; Dong-Ryeol Ryu; Tae-Hyun Yoo; Shin-Wook Kang
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

8.  Close association of arterial plaques with left ventricular hypertrophy and ejection fraction in hemodialysis patients.

Authors:  Morteza Mowlaie; Hamid Nasri
Journal:  J Nephropharmacol       Date:  2014-01-01

Review 9.  FGF23, Biomarker or Target?

Authors:  Cristian Rodelo-Haad; Rafael Santamaria; Juan R Muñoz-Castañeda; M Victoria Pendón-Ruiz de Mier; Alejandro Martin-Malo; Mariano Rodriguez
Journal:  Toxins (Basel)       Date:  2019-03-22       Impact factor: 4.546

Review 10.  FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?

Authors:  Robert Stöhr; Alexander Schuh; Gunnar H Heine; Vincent Brandenburg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.